{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field de7b2791-dbfd-4aa8-a48e-280e30db503d --><h2>Changes</h2><!-- end field de7b2791-dbfd-4aa8-a48e-280e30db503d -->","summary":null,"htmlStringContent":"<!-- begin item 7369a9e6-8d34-4d1d-940c-b3a726bafecd --><!-- begin field 4ab9b21f-aacd-4c67-a35f-366fdba4ab2e --><p><strong>September 2019 </strong>— minor update. The section on management of oral candida in children, and the prescribing section have been updated to clarify that the use of oral miconazole gel in children aged under 4 months is unlicensed.</p><p><strong>August 2017 </strong>— minor update. Changes to the drug interactions section for miconazole gel in accordance with changes to the manufacturer's summary of product characteristics. </p><p><strong>May 2017 </strong>— reviewed. A literature search was conducted in April 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to recommendations have been made, but the topic has been restructured.</p><!-- end field 4ab9b21f-aacd-4c67-a35f-366fdba4ab2e --><!-- end item 7369a9e6-8d34-4d1d-940c-b3a726bafecd -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"66bad706-85d8-519f-826e-8aa3955740bb","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field cc52b8b6-2b16-491b-b674-33004c2fc042 --><h3>Previous changes</h3><!-- end field cc52b8b6-2b16-491b-b674-33004c2fc042 -->","summary":null,"htmlStringContent":"<!-- begin item 037c01eb-e516-4584-a833-7bc3429f583f --><!-- begin field 55340659-08a2-4e69-8119-13856f0401d6 --><p><strong>December 2016</strong> — minor update. The adverse effects of miconazole oral gel have been updated in line with the manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>November 2016</strong> — minor update. The use of miconazole gel in people taking warfarin has been clarified, to take into account the Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update <em>Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin</em>. </p><p><strong>January 2014 </strong>— minor update. Text updated in line with the SPC for miconazole oral gel in the Prescribing Information<em> </em>section to highlight the risk of choking in infants and young children when miconazole oral gel is applied to the mouth.  </p><p><strong>December 2013 </strong>— minor update. Text updated to reflect that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections.</p><p><strong>August 2013 </strong>— minor update to the text to reflect recent guidance from the EMA regarding the use of oral ketoconazole.</p><p><strong>July 2013 </strong>— reviewed. A literature search was conducted in June 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"5f85a852-1e06-49ed-826e-a98c01121f1e\">www.medicines.org.uk</a>) have been updated.</p><p><strong>October 2009 </strong>— minor update. Minor wording change regarding the use of miconazole oral gel in children aged 4 months and younger. Issued in October 2009.</p><p><strong>April to September 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the Changes<em> </em>section. Issued in September 2008.</p><p><strong>May 2008 </strong>— minor update to remove nystatin pastilles because they have been discontinued. Text regarding nystatin pastilles has been removed as well as prescriptions. Minor update to text to reflect the change in licence for miconazole oral gel. Issued June 2008.</p><p><strong>April 2008 </strong>— minor update to the text for oral ketoconazole to reflect the most recent MHRA guidance.</p><p><strong>July 2007 </strong>— minor update to text and prescription added for miconazole oral gel (children under 2 years).</p><p><strong>July to September 2006 </strong>— reviewed. Validated in December 2006 and issued in January 2007. This guidance has been reviewed, restructured and updated following a full literature review. There are no major changes to the recommendations. An evidence section has been added.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>October 2003 </strong>— written. Validated in December 2003 and issued in February 2004.</p><!-- end field 55340659-08a2-4e69-8119-13856f0401d6 --><!-- end item 037c01eb-e516-4584-a833-7bc3429f583f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}